Slide 1: 2Q 2024 Earnings Call
2Q 2024 Earnings Call August 6, 2024
Slide 2: Agenda
Agenda Ameet Mallik 01 Chief Executive Officer Business Update Pepe Carmona Financial Update 02 Chief Financial Officer 03 Q&A 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 4: Unlocking Potential Value of Our Robust ADC Portfolio
Unlocking Potential Value of Our Robust ADC Portfolio Hematology Portfolio Solid Tumor Portfolio Short-Mid Term Mid-long Term ZYNLONTA ADCT-601 (AXL) § Maximize ZYNLONTA in 3L+ DLBCL § Optimizing dose for expansion as single agent and / or in combination in sarcoma, pancreatic, and NSCLC § Seek to e
Slide 5: Key Business Updates
Key Business Updates § ZYNLONTA® reached commercial profitability in 1H 2024 Commercial § Revenues of $34.9 million year-to-date, 2Q 2024 revenues of $17.0 million product sales Performance § Potential to further strengthen market presence in an increasingly competitive environment § LOTIS-5 passed
Slide 6: Advancing ZYNLONTA Development in B-Cell Lymphomas
Advancing ZYNLONTA Development in B-Cell Lymphomas Projected U.S. Market Value2, 2023 5-year prevalence3 Current Development Areas DLBCL FL MZL^ $3.1b2, ~109 K patients $2.6b2, ~61 K patients $1.4b2, ~38 K patients § LOTIS-5 and LOTIS-7 potential to move ZYNLONTA into 2L+ DLBCL ‒ LOTIS-5 (ZYNLONTA +
Slide 7: ADCT-601 Targeting AXL: Rationale and Differentiation
ADCT-601 Targeting AXL: Rationale and Differentiation TARGET RELEVANCE AXL EXPRESSION1 % of cases with high % of cases with any AXL expression AXL Expression § AXL is expressed in multiple tumor types - including NSCLC, Sarcoma (STS) ~30% ~90% pancreatic, and sarcoma Pancreatic adenocarcinoma ~35% 6
Slide 8: Developing Differentiated ADCs with a High Therapeutic Index
Developing Differentiated ADCs with a High Therapeutic Index A novel hydrophilic, highly stable, protease-cleavable linker conjugated to Exatecan NaPi2b Claudin-6 PSMA ASCT2 Target description Phosphate transporter Adhesion protein Enzymatic glycoprotein Amino acid transporter NSCLC NSCLC NSCLC Tumo
Slide 9: 2Q 2024 Selected Financial Data (in $ millions)
2Q 2024 Selected Financial Data (in $ millions) Balance Sheet June 30, 2024 Cash and cash equivalents $300.1 GAAP Non-GAAP (Adjusted)* Statement of Operations 2Q 2024 % vs. 2Q 2023 2Q 2024 % vs. 2Q 2023 Product Revenues, Net 17.0 -11.3 17.0 -11.3 Research & Development Expenses 24.3 -22.5 23.9 -23.9
Slide 10: Corporate Business Development Strategy for ADCT Portfolio
Corporate Business Development Strategy for ADCT Portfolio U.S. EX-U.S. HEMATOLOGY OVERLAND ZYNLONTA, ADCT-602 JOINT VENTURE Direct Partnership Business Development to Unlock Value SOLID TUMORS ADCT-601, Research Assets Co-development & Royalty & Co-promote* Milestones to ADCT Business Development G
Slide 11: Delivering on Our Strategy
Delivering on Our Strategy Milestones Achieved q LOTIS-7: Cleared dose escalation q r/r FL and r/r MZL IITs: Encouraging initial data shared q ADCT-601 (AXL): Dosing initiated in pancreatic q Research platform: Highlighted at Investor Event q ZYNLONTA: Achieved commercial brand profitability* in 1H
Slide 12: 2Q 2024 Earnings Call
Earnings Call . THERAPEUTICS Innovating Science. Inspiring Hope.
Slide 13: Reconciliation of GAAP Measures to Non-GAAP Measures
Reconciliation of GAAP Measures to Non-GAAP Measures Unaudited (in thousands) in #039;000 2Q 2024 2Q 2023 Net loss (GAAP) $ (36,544) $ (48,922) Adjustments: Share-based compensation expense (reversal) - R&D (i) 408 (61) Share-based compensation expense (reversal) - S&M (i) 197 (619) Share-based compens